How to Evaluate a Biotechnology Company Before You Invest

Biotechnology companies are difficult to evaluate because the thing an investor is being asked to value is often still being developed.

There may be no revenue, no approved product, limited clinical evidence, substantial future costs, uncertain timelines, and several important decisions that have not yet been made. Yet the company may already have a meaningful valuation based on what investors believe the technology could eventually become.

That creates a fundamental problem. You are not simply evaluating what the company has. You are evaluating what the company is likely to become, and how much evidence exists to support that expectation.

For an investor coming from a conventional business background, this can be an unfamiliar way to think about value. A company with a promising technology can have very little current revenue and still be valuable. A company with impressive scientific results can also be a poor investment if the path from those results to a commercially successful product is too uncertain, too expensive, too long, or insufficiently protected.

The first step is therefore not choosing a valuation method. It is understanding what you are actually being asked to believe.

Start with the proposition

A biotech investment thesis usually contains a chain of claims. The underlying biology is expected to be meaningful. The technology is expected to produce the desired effect. That effect is expected to translate into a useful outcome. The development program is expected to demonstrate that outcome. Regulatory requirements are expected to be satisfied. The resulting product is expected to reach a market. Patients, physicians, payers, or other customers are expected to adopt it.

A company does not need to have proven every one of these things before it becomes investable. But an investor does need to know which parts have been demonstrated and which parts remain assumptions.

What has the company actually shown, and what are you being asked to believe beyond the evidence?

This is one of the most important questions in biotech evaluation because a compelling presentation can make the entire chain feel equally established. It is not.

A preclinical result may provide evidence that a biological mechanism can produce an effect under particular experimental conditions. It does not establish that the same effect will occur in humans, that it will be clinically meaningful, or that the eventual product will be commercially successful. Likewise, an early clinical result can be encouraging without resolving the questions that will determine whether a treatment can ultimately succeed.

The task is not to dismiss the company's assumptions. The task is to separate evidence from inference. That distinction gives you a much better starting point for evaluating the company.

Ask what the evidence actually tells you

The amount of evidence can be misleading. A company may have generated years of research, numerous publications, extensive laboratory data, and several interesting findings. Another company may have a relatively small dataset that directly addresses a critical uncertainty. Which one is more valuable?

The answer depends on what you are trying to establish.

The FDA's drug development framework illustrates why evidence has to be interpreted in context. Different stages of development are designed to answer different questions. Preclinical work supports the decision to begin testing in humans. Early clinical studies provide information including safety, tolerability, pharmacokinetics, and other early findings. Later studies provide the evidence needed to evaluate the treatment more comprehensively.

So the relevant question changes as the program advances.

What important uncertainty is the next stage of development supposed to resolve?

This question forces the evaluation away from simply counting positive findings. If the company is entering Phase 2, for example, the important issue may not be whether the mechanism is interesting. It may be whether the earlier evidence provides a credible basis for expecting a meaningful clinical effect in the population now being studied.

If the company is preparing for a pivotal study, the questions become different again. The design, endpoint, patient population, effect size, statistical assumptions, operational requirements, and regulatory expectations all become increasingly consequential.

The evidence needs to be judged against the decision it is being used to support. Good evidence is not merely evidence that exists. It is evidence that meaningfully reduces an important uncertainty.

Follow the evidence into the development program

A scientific finding has to become a development program before it can become a product. This is where an investment analysis can become disconnected from the science.

A company may have a scientifically credible mechanism and still face difficult development questions. The appropriate dose may not be established. The treatment may produce an effect that is smaller in humans than expected. Patient recruitment may be difficult. The relevant population may be narrower than anticipated. Manufacturing may introduce new problems. The study may produce an ambiguous result that requires additional work.

None of these possibilities means the underlying science is poor. They mean the path from scientific evidence to a useful product contains additional uncertainties.

What has to happen between the company's current position and the outcome on which the investment thesis depends?

Writing that path down can be surprisingly revealing. If the company is in early clinical development, the answer may involve several future studies, additional financing, regulatory interactions, manufacturing development, and years of work. Each step creates another point at which the original thesis can change.

This is why development stage matters so much when evaluating a biotech company. The same technology can represent a very different investment opportunity depending on how much has already been demonstrated and how much remains to be proven.

Do not confuse a development plan with a development outcome

A company will normally have a development plan. That plan may be scientifically reasonable and professionally constructed. It may even have been reviewed by experienced people. It is still a plan.

Which parts of the company's timeline are supported by evidence, and which parts depend on everything proceeding according to plan?

The distinction matters because delays are not economically neutral. A longer clinical program can mean additional operating costs, additional financing, dilution, delayed revenue, and a later commercial launch. It can also change the competitive environment during the time the company is developing its product.

The question is therefore not simply whether management has estimated that Phase 2 will take two years. The question is why two years is a reasonable assumption, what could make it longer, and what happens to the investment case if it does.

This does not require assuming that everything will go wrong. It requires understanding which assumptions are carrying the most weight.

The commercial question begins before approval

It is tempting to postpone commercial analysis until the science has been proven. That can be a mistake because the eventual commercial opportunity influences how much development risk is worth taking today.

A product can address a large disease population and still have limited commercial potential. Conversely, a treatment for a smaller population may have substantial value if it addresses a serious unmet need and provides meaningful clinical benefit.

The relevant question is not simply how many people have the disease.

Who will actually use this product, why would they use it, and what has to be true for that use to become economically meaningful?

That requires looking beyond the company's estimate of market size. What is the current standard of care? What problem does the new technology solve? Is the proposed benefit meaningful enough to change behavior? Are there competing treatments? Who pays for the treatment? What constraints could affect adoption?

These questions do not require a complete commercial forecast at the earliest stage of development. They do require enough understanding to determine whether the commercial premise is plausible.

Look at the competition that may exist when the product arrives

A common mistake is to evaluate competition based only on what is available today. A biotech company developing a product over several years is not competing in today's market. It is trying to enter a future market.

What might the competitive landscape look like when this product is ready, rather than when the investment is being made?

An apparently empty market may not remain empty. Another company may be developing a different mechanism for the same disease. An existing treatment may improve. A competing technology may reach patients first. A new standard of care may change what physicians consider an adequate benefit.

This is particularly important when the investment thesis depends on a product eventually achieving substantial market share. The absence of an approved competitor today does not necessarily mean the company will have a large uncontested market later.

Intellectual property needs to be considered in the context of time

Intellectual property can be a critical component of biotechnology value, but the existence of a patent is not the same as having a long period of commercial protection remaining.

A patent may have been filed years before the product reaches the market. The company may therefore spend a substantial portion of its patent term during research and development.

How much commercially useful protection will remain if the development program succeeds?

That question is more useful than simply asking whether the company has patents. Regulatory exclusivity can also affect the competitive landscape, and FDA distinguishes regulatory exclusivity from patent protection. The two can interact, but they are not interchangeable.

The important investment consideration is therefore the period during which the company can realistically benefit from its intellectual property and regulatory position.

This brings together two questions that are often considered separately: How long will it take to reach the market, and how much protected commercial opportunity will remain when it gets there?

Those questions belong in the same analysis.

Now ask what could break the thesis

At this point, the evaluation should become more specific. You know what the company is trying to establish. You have considered what the evidence actually demonstrates. You have looked at the development path, the commercial premise, the competition, and the protection around the eventual product.

Now turn the analysis around.

What would have to go wrong for the investment thesis to stop working?

The answer should not simply be "the drug fails." There can be many ways for an investment thesis to weaken without producing a complete scientific failure.

The treatment could work, but produce a smaller benefit than expected. The treatment could work, but only in a smaller patient population. The clinical program could succeed, but take substantially longer than expected. The product could reach approval, but face stronger competition than anticipated. The technology could work, but manufacturing costs could undermine the economics. The company could continue to require capital long enough that dilution materially changes the investment outcome.

These possibilities are different, and they do not all deserve the same weight.

The purpose of identifying them is to determine which uncertainties could actually change the value of the company.

Only then should valuation begin

Once the scientific, development, commercial, competitive, and intellectual-property questions have been examined, the valuation becomes much more meaningful.

There is no single valuation method that solves the problem for every biotechnology company. The appropriate approach depends on the development stage, available evidence, expected future cash flows, assets, comparables, transaction data, and the uncertainty surrounding the program.

Risk-adjusted approaches are often useful because a biotechnology asset may generate substantial value in a successful outcome while having a meaningful probability of failing before reaching that outcome.

But the spreadsheet is not the analysis. A valuation model can calculate an extraordinarily precise answer from assumptions that have never been properly examined.

If changing one uncertain assumption dramatically changes the valuation, how much confidence should you place in the resulting number?

This is where the earlier work becomes important. The valuation should make the assumptions visible rather than hide them inside a single number.

If the value depends heavily on an aggressive development timeline, that should be apparent. If it depends on a particular clinical outcome, that should be apparent. If it depends on a large commercial market, limited competition, or a long period of effective exclusivity, those assumptions should also be apparent.

The goal is not to produce a number that looks precise. The goal is to understand what would have to be true for the number to make sense.

A better way to think about biotech evaluation

A biotech company should not be evaluated as though it were simply a small version of an established business. The company may have little current revenue precisely because it is spending years trying to establish whether a future product can exist.

That means the evaluation has to move through the chain:

The connections between those elements matter as much as the elements themselves.

A compelling biological result is less compelling if it does not translate into a realistic development path. A strong development program is less valuable if the eventual market is weak. A large market is less valuable if the product cannot obtain a meaningful position within it. A promising product is less valuable if development consumes most of the commercially useful period of protection. And a sophisticated valuation is less useful if its most important assumptions have never been challenged.

The central task in biotech diligence is therefore not to decide whether a company is promising. It is to determine which parts of the promise have evidence behind them, which parts remain assumptions, and how much those assumptions matter to the eventual outcome.

That is where an investment decision can move from a compelling story toward an informed assessment.

← Back to Insights

Explore Insights

The questions examined here connect to broader areas of scientific, technical and strategic assessment. Explore the other areas of Insights as they develop.